AstraZeneca expects vaccine data this year, sales beat estimates

This post was originally published on this site

The company reiterated it expected results from the late-stage trials on its experimental COVID-19 vaccine later this year, depending on the rate of infection among trial participants.

Product sales, which exclude payments from collaborations, rose 7% to $6.52 billion for the three months ended Sept. 30 on a constant-currency basis, ahead of a company-compiled consensus of $6.50 billion.

However, the company reported core earnings of 94 cents per share, lower than analysts’ expectations of 98 cents.